• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthDigital Health

Chinese Doctor Who Created Gene-Edited Embryos Is Sentenced to Three Years in Prison

By
Sy Mukherjee
Sy Mukherjee
By
Sy Mukherjee
Sy Mukherjee
December 30, 2019, 3:05 PM ET

He Jiankui shocked the world in 2018 when he revealed that he’d used CRISPR technology, or gene editing, on babies—the first such application in history. Now, a Chinese court has sentenced him to three years in prison and a $430,000 fine for the controversial experiment, which is considered illegal since it involves CRISPR gene editing in reproduction, according to China’s Xinhua news agency.

He and associates allegedly carried out gene-editing experiments on embryos that led to the birth of three gene-edited “CRISPR babies.” Zhang Renli and Qin Jinzhou were also sentenced to more than two years in prison, albeit with a reprieve, in the case.

The process was meant to prevent these babies from being infected with HIV from a parent—though the scientific community including CRISPR pioneers Jennifer Doudna and Feng Zhang, along with drug makers, widely condemned the experiment.

It’s unclear how these babies are currently doing, though there have been no reports of adverse events.

A district court in Shenzhen ruled that He and his partners had conducted the embryonic gene-editing experiments “in the pursuit of personal fame and gain” and have seriously “disrupted medical order.” He’s partners

He has previously defended his efforts, even saying that he was “proud” of the results.

In Coins2Day‘s recent list of 25 ideas which will shape the 2020s, Doudna—a University of California at Berkeley professor and executive director of the Innovative Genomics Institute—addressed the ethical controversies that still dog gene editing, including He’s actions.

“I certainly hope that over the coming decade we see an increasing global effort to put in place appropriate regulations for using genome editing, especially in applications that could have a very profound impact on everyone,” she told Coins2Day.

Gene editing has been hailed for its potential to help treat diseases like cancer and sickle cell anemia. But the technology remains in its earliest stages. And as this case shows, ethical questions remain a significant concern.

More must-read stories from Coins2Day:

—25 ideas that will shape the 2020s
— Why there’s no room for your carry-on bags in the overhead bin
—UPS’s $20 billion bet on e-commerce is paying off
—Airbnb copes with a bad trip on the road to a 2020 IPO
—Electronic health records are creating a ‘new era’ of health care fraud
Subscribe to Coins2Day’s Eye on A.I. Newsletter, where artificial intelligence meets industry.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.